Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» JAK inhibitors
JAK inhibitors
AbbVie's Rinvoq label portends safety warnings for future JAKs—including Gilead's
Fierce Pharma
Tue, 08/20/19 - 09:45 am
JAK inhibitors
AbbVie
Rinvoq
FDA
Gilead Sciences
Watch out AbbVie: Gilead is fast on your heels at the FDA with rival JAK inhibitor filgotinib
Endpoints
Tue, 07/2/19 - 10:46 am
Gilead Sciences
AbbVie
FDA
JAK inhibitors
filgotinib
Upadacitinib
rheumatoid arthritis
Pfizer jumps into the heated PhIII race for new-wave JAK inhibitors — but safety frets loom large
Endpoints
Wed, 05/15/19 - 10:24 am
Pfizer
JAK inhibitors
abrocitinib
anti-inflammatories
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Endpoints
Fri, 03/1/19 - 12:07 pm
Pfizer
Europe
JAK inhibitors
Xeljanz
Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Fierce Pharma
Sat, 02/23/19 - 04:32 pm
Pfizer
Xeljanz
JAK inhibitors
Could Gilead and Galapagos' JAK inhibitor lead the class? Wall Street thinks it has a chance.
Biopharma Dive
Mon, 11/26/18 - 11:13 pm
Gilead Sciences
Galapagos
JAK inhibitors
rheumatoid arthritis
filgotinib
Concert’s initial alopecia data fall short against Pfizer, prompting investor blow back
Endpoints
Tue, 11/13/18 - 09:50 am
Concert Pharmaceuticals
alopecia
JAK inhibitors
Pfizer
CTP-543
Pfizer’s JAK inhibitors improve hair regrowth in patients with alopecia areata
Pharmaceutical Business Review
Mon, 09/17/18 - 09:52 am
Pfizer
JAK inhibitors
alopecia areata
clinical trials
PF-06651600
PF-06700841
Jefferies says Gilead is poised for turnaround—and JAK inhibitor could be key
Fierce Biotech
Thu, 07/5/18 - 07:42 pm
Gilead Sciences
JAK inhibitors
filgotinib
rheumatoid arthritis
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
Wed, 06/6/18 - 11:31 am
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Wed, 05/23/18 - 09:54 am
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
Can Johnson & Johnson Replace Remicade for $100 Million Upfront?
Motley Fool
Wed, 02/21/18 - 09:40 am
JNJ
Remicade
TD-1473
Theravance
JAK inhibitors
inflammatory bowel disease
J&J strikes potential $1B JAK inhibitor deal with Theravance
Biopharma Dive
Wed, 02/7/18 - 10:06 am
JNJ
JAK inhibitors
Theravance
TD-1473
drug development
Crohn's Disease
ulcerative colitis
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
Tue, 09/12/17 - 04:22 pm
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
Sun, 09/10/17 - 11:56 am
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
Fri, 06/23/17 - 03:37 pm
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
AbbVie's JAK-1 inhibitor hits the mark in Crohn's disease
BioPharma Dive
Thu, 05/11/17 - 11:17 am
AbbVie
JAK inhibitors
Crohn's Disease
Upadacitinib
Will Sales of Xeljanz Offset Falling Sales of Enbrel?
Market Realist
Tue, 09/6/16 - 09:47 am
Pfizer
Xeljanz
Enbrel
rheumatoid arthritis
JAK inhibitors
With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy
Medical Marketing and Media
Wed, 05/11/16 - 10:52 am
Eli Lilly
baricitinib
JAK inhibitors
Pfizer
Xeljanz
Enbrel
AbbVie
Humira
JNJ
Remicade
JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials
Fierce Biotech
Thu, 02/11/16 - 08:58 pm
Incyte
Jakafi
solid tumors
JAK inhibitors
Pages
« first
‹ previous
1
2
3
4
next ›
last »